

ERYTECH strengthens its intellectual property portfolio

- Patent « Medicament for the Treatment of Cancer of the Pancreas» allowed in Europe
- Patent « Lysis/Resealing Process for Preparing Erythrocytes» allowed in India

Lyon (France), June 2nd, 2014 – ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, announces the granting of two key patents for its core product ERY-ASP.

ERYTECH recently received notice of allowance from the European Patent Office of a key patent covering its lead product ERY-ASP for the treatment of pancreas cancer. The patent entitled “*Medicament for the Treatment of Cancer of the Pancreas*” was filed in late 2007 and has in the meantime been granted in Australia, Israel and Singapore. For reminder, ERYTECH has received at the beginning of May the green light from the French Medicines Agency (ANSM) for a Phase II study with ERY-ASP in pancreas cancer. The study is expected to enroll first patients in the coming months.

ERYTECH’s core process patent was also recently granted in India. This patent entitled “*Lysis/Resealing Process for Preparing Erythrocytes*” is the core protection of the technology platform and products developed by ERYTECH. With this additional grant ERYTECH proprietary technology benefits from a broad coverage internationally. The patent application that was filed in 2004 was already granted in Europe, USA, Japan, China, Hong-Kong, Australia and South-Korea.

“These additional patent grants further strengthen ERYTECH’s intellectual property position and confirm the uniqueness of our encapsulation technology for the development of safer and longer acting drugs using red blood cells as a vehicle”, comments Gil Beyen, CEO of ERYTECH.

ERYTECH participates at the following events:

- Jefferies Global Healthcare Conference, June 2-5 in New York
- Village des Actionnaires, June 12 in Lyon
- French Life Science Days, June 25-26 in New York

About pancreas cancer:

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. Every year about 45,000 patients are diagnosed with pancreatic cancer in the US, and about 80,000 in Europe. According to the American Cancer Society, for all stages of pancreatic cancer combined, the one-year relative survival rate is 20%, and the five-year rate is 6% to 10%. Pancreatic cancer is currently the fourth most common cause of cancer death in the EU for men and women. Death rates from the disease are predicted to rise from 7.8 in 2009 to 8.0 in 2013 per 100,000 among men, and from 5.3 to 5.5 per 100,000 among women in same period. In fact, the pancreas is the only major cancer site for which no improvements in mortality rates is predicated¹.

¹ Malvezzi M et al., *Annals of Oncology* 2013, 1-9

About ERYTECH and ERY-ASP/GRASPA®: www.erytech.com

Created in Lyon in 2004, ERYTECH is a French biopharmaceutical company providing new prospects for cancer patients, particularly those with acute leukemia and selected solid tumors.

By encapsulating the asparaginase enzyme in red blood cells, ERYTECH has developed ERY-ASP/GRASPA®, an original treatment that targets cancer cells through “tumor starvation” while significantly reducing the side effects for patients. ERY-ASP/GRASPA® is currently completing Phase III clinical development in Acute Lymphoblastic Leukemia (ALL) and is in Phase IIb clinical trial in Acute Myeloid Leukemia (AML) in Europe. The product is also in Phase I/II clinical development in ALL in the USA.

Every year about 50,000 patients are diagnosed with Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML), the two forms of acute leukemia. Today, for about 80% of these patients, mainly adults and relapsing patients, current forms of asparaginase cannot be used due to their toxicity. With a presumed improved safety profile, ERY-ASP is being developed to allow all leukemia patients to be treated, even the most fragile ones, representing a market opportunity of more than EUR 1 billion. ERYTECH has concluded licensing and distribution partnership agreements for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL with TEVA in Israël.

The company is also developing other indications in solid tumors and certain orphan indications outside oncology. The company is currently launching a Phase II study in pancreas cancer and it exploring other solid tumor indications.

ERYTECH has its own GMP-approved and operational manufacturing site in Lyon (France), and a site for clinical production in Philadelphia (USA).

ERYTECH is listed on Euronext regulated market in Paris. (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharm. & Bio and Next Biotech indexes.

Forward-looking information

This document may contain forward-looking statements and estimates with respect to the financial situation, the results of operations, the strategy, the project and to the anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of ERYTECH, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amf-france.org), also available on our website (www.erytech.com) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by French law.

CONTACTS

ERYTECH

Gil Beyen
Chairman & CEO
Pierre-Olivier Goineau
Vice President and COO
Tel: +33 4 78 74 44 38
investors@erytech.com

NewCap.

Julien Perez / Emmanuel Huynh
Investor and press relations
Tel: +33 1 44 71 98 52
erytech@newcap.fr

